Research and Development Collaboration Clause Samples
The Research and Development Collaboration clause establishes the terms under which two or more parties agree to work together on research and development activities. It typically outlines the scope of the collaboration, the roles and responsibilities of each party, and how intellectual property resulting from the joint efforts will be managed. For example, it may specify how costs are shared, how confidential information is protected, and how results or inventions are owned or licensed. The core function of this clause is to provide a clear framework for cooperation, ensuring that each party’s contributions and rights are defined to prevent disputes and facilitate successful joint innovation.
POPULAR SAMPLE Copied 2 times
Research and Development Collaboration. Both parties commit to collaborate on joint research endeavors during the agreed-upon duration, contributing to the advancement of architectural knowledge and practices.
Research and Development Collaboration. The Parties agree the Research and Development Services Agreement, entered into between the Parties on September 20, 2013, shall remain in full force and effect for the duration of the term thereof, including all amendments formally made in writing and executed by both Parties.
Research and Development Collaboration. Collaboration Target, and First Program Antibody.
Research and Development Collaboration. 2.1 OVERVIEW. The primary purpose of the Collaboration is to conduct Research and Development toward the discovery and development of Collaboration Products in accordance with the Annual Research Plan. To that end, it is contemplated by the parties that:
(a) Neurocrine will have primary responsibility for supplying certain cell lines necessary for the study of glial cell activation, providing small molecule compounds from the Neurocrine Chemical Library, performing limited medicinal chemistry as required by the Annual Research Plan, and conducting certain screening and secondary assays and screening compounds from the Neurocrine Chemical Library against Rigel Targets;
(b) Neurocrine and Rigel will share responsibility for applying the Rigel Technology to develop an appropriate glial cell assay system to identify Protein Targets and Peptide Antagonists; and
(c) Rigel will have primary responsibility for identifying and providing Protein Targets, identifying and sequencing gene(s) coding for the Protein Targets, and generating, identifying and providing Peptide Antagonists of such Protein Targets. Rigel will also have responsibility for providing Rigel Targets to Neurocrine for screening purposes. It is understood that the individual and joint responsibilities will be set forth in detail in the Annual Research Plan to be developed pursuant to Section 3.2.
Research and Development Collaboration. The Parties agree that they are open to exploring future collaboration(s) for mutually agreed upon research and development projects or clinical research or trials and entering into a cost-sharing arrangement for such endeavors.
Research and Development Collaboration. In order to transition the continued research, Kosan Know-How, and initiate Phase I development of KOS-2187, the Parties will agree [*] to the Joint Research and Development Plan, as may be amended or supplemented from time to time by the Parties (the “Joint Research and Development Plan. The agreed elements of the Joint Research and Development Plan are attached as Exhibit C. If the Parties are unable to agree on the Joint Research and Development Plan, Licensee shall have the right to make any final decisions relating to development activities. Kosan shall use commercially reasonable efforts to conduct, on behalf of Licensee, the research and development activities set forth in the Joint Research and Development Plan. In conducting the Joint Research and Development Plan, Kosan shall comply with all applicable laws, regulations and generally accepted principles of good clinical practice. Licensee will pay Kosan its reasonable costs, as agreed in advance by the Parties, for its work under the Joint Research and Development Plan. Such payments shall be made on a quarterly basis within sixty (60) days after receipt of Kosan’s invoice therefor. Any taxes or withholding on the payments to be made by Licensee under this Section 6.4 (other than taxes on Kosan’s income) shall be borne by Licensee. Any invention covering the manufacture, use or sale of a compound within the Kosan Compound Library conceived or reduced to practice by employees or agents of Kosan or Licensee in performance of the Joint Research and Development Plan shall be [*] owned by [*], such inventions shall [*] and [*]. All data and information generated in the performance of the Joint Research and Development Plan shall be owned by [*] and shall be considered [*] Confidential Information, subject to the exceptions set forth in Section 10.3. Except for accrued obligations, and unless otherwise agreed by the Parties, the Parties’ obligations under the Joint Research and Development Plan shall terminate upon Commencement of the first Phase II trial for Licensed Product. In the event Licensee decides to initiate development activities with respect to a compound within the Kosan Compound Library other than KOS-2187 during the term of this Agreement, Licensee shall notify Kosan, and the Parties shall discuss whether Licensee is interested in having Kosan assist in any such activities under an amended Joint Research and Development Plan. In the event Kosan undergoes a Change of Control, Licensee sha...
Research and Development Collaboration